Development of local generic version of Pfizer Vax; China asks for license; Report
Beijing: It has been reported that China is preparing to sign an agreement with the American multinational pharmaceutical company Pfizer Inc.
China and Pfizer are in talks over a license to produce a regional generic version of Pfizer’s Paxlovid vaccine amid the spread of a new variant of Covid in China, Reuters reported, citing various sources.
Once licensed, domestic pharmaceutical companies in China will be able to manufacture and distribute the generic version of the Paxlovid vaccine in China.
According to the report, discussions with Pfizer are ongoing under the guidance of the National Medical Products Administration (NMPA), China’s medical products regulator. Talks began last month.
China aims to reach a final decision on the terms of the deal before the Lunar New Year, which starts on Jan. 22, the report said.
Meanwhile, since the “Zero Covid Policy” was dropped last month, Chinese hospitals are facing a major crisis due to overcrowding of Covid patients.
China approved the paxlovid vaccine in February last year.
Highlight: Report says China is in talks with Pfizer for a generic COVID drug
